William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the current status of measurable residual disease (MRD) in clinical practice for chronic lymphocytic leukemia (CLL). He believes that it is not yet ready for widespread adoption, but it shows promise for future standard care in patient management. He emphasizes the need for more data showing that achieving undetectable MRD improves long-term outcomes, as well as the necessity for standardized assays. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
